AAV manufacturing growth ProBio recently launched GMP Adeno-Associated Virus manufacturing at a large 128,000-square-foot facility in Hopewell, signaling expanded capacity and capabilities to attract gene therapy developers needing end-to-end viral vector production.

North America expansion With a dedicated US hub for plasmid DNA and viral vector production and a US site head overseeing operations, ProBio is well positioned to win US-based CDMO engagements from biotech firms seeking regional, reliable supply and local project leadership.

Therapeutic focus ProBio targets advanced therapies including biologics, protein and mRNA vaccines, viral vectors and antibody-drug conjugates, aligning with current market demand for versatile manufacturing partners across gene therapy, cell therapy and protein therapeutics.

Strategic leadership Recent executive hires and leadership changes, including the CEO appointment in late 2024 and US leadership roles, indicate a strategic push to scale capabilities, enter new partnerships, and accelerate deal-making with large and mid-size biotechs.

Publications and outreach ProBio’s active participation in industry events and multiple press releases in 2024–2025 suggest ongoing marketing and collaboration opportunities, making it easier to approach for joint presentations, WIP demonstrations, or sponsored forums to showcase capabilities.